Senovance is an age-related disease biotechnology company built on SenoReverse™, a proprietary miRNA platform that reverses senescent cell-cycle arrest. First-in-human dosing was completed in 2026.
SenoReverse™: one mechanism and one chemistry across all programs.
Therapeutics and consumer healthcare.
Systemic lead program in sarcopenia.
Scientific rigor. Mechanism-driven.
Evidence first.
Senovance applies a single mechanism across two lines of business. In therapeutics, the systemic lead program is advancing toward an Investigational New Drug (IND) submission, and first-in-human dosing was completed in 2026. In consumer healthcare, the product line is registered and commercial rollout is underway.
The company is backed by institutional venture investors with a multi-year investment horizon in aging biology.
Senovance holds both lines to one standard: claims are made only where the mechanism supports them, evidence is established before the wording is chosen, and every consumer claim rests on instrument-graded human studies run by an independent laboratory.
Internationally recognized scientists in aging biology, holding professorships and academy appointments in cell senescence and regenerative medicine.
Senior pharmaceutical clinical-development executives with experience leading global clinical organizations, spanning trial design and regulatory pathways.
Investigator-initiated programs conducted with two academic clinical centers, spanning sarcopenia, neurodegeneration, and dermatological indications.
Senovance is backed by institutional venture investors who share a multi-year horizon in aging biology and who fund the path from mechanism, through human evidence, to medicine.
A registered consumer product line, now in commercial rollout, operates alongside the pipeline and generates cash flow, brand presence, and external validation of the platform while the therapeutics programs advance.
Muscle half-life and duration of target engagement following subcutaneous dosing.
The systemic lead program in sarcopenia.
Two lead indications: sarcopenia and androgenetic alopecia.